Moderna, Inc. (MRNA) is gaining investors’ attention after unveiling promising data from its latest flu vaccine trial. The biotech firm’s reformulated version of its messenger-RNA-based flu shot met its primary goals in a final-stage trial, paving the way to seek regulatory approval for the influenza vaccine.
Amid declining sales of its COVID-19 vaccines due to pandemic fatigue, MRNA is strategizing to expand its product portfolio and identify new revenue streams.
